Alkermes (ALKS) Stock
Mid cap biotech developing brain and addiction treatments. Here's the price, business snapshot, and what's worth knowing about Alkermes in October 2026.
Alkermes plc (ALKS) is a biopharmaceutical company focused on developing medicines for people living with serious neuropsychiatric, neurologic and addiction disorders. The company combines proprietary formulation and delivery technologies with a pipeline that includes marketed products and earlier-stage candidates. Its revenues come from product sales, royalties and partner collaborations, while research and development is a major cost driver. Investors should be aware that Alkermes is R&D‑intensive and sensitive to clinical trial results, regulatory approvals and reimbursement decisions — outcomes that can materially affect valuation. With a market capitalisation around $5.2bn, Alkermes occupies a mid-cap position in the biotechnology sector, offering exposure to neuroscience therapeutics but also carrying typical sector volatility. This summary is educational only and not personal financial advice; prospective investors should review the company’s latest filings and consider their own risk tolerance.
Alkermes (ALKS) Stock Forecast
Analyst price target, next 12 months
$48.12
+15.3% vs today's $41.75
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Alkermes have a consensus 12-month target of $48.12, above the current price of $41.75.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Alkermes stock, anticipating it could reach a higher price soon.
Financial Health
ALKERMES PLC is showing strong revenue and profit margins, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical and regulatory milestones can move the share price; watch study readouts and approvals, though outcomes are uncertain.
R&D Intensity
High R&D spending supports innovation but increases cash-burn risk; funding and trial success are important to monitor.
Commercial & Partnerships
Revenue is a mix of product sales, royalties and collaborations; commercial uptake and payer decisions influence growth, and competition remains.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
